Hemikaa Devakumar
Urogynecology and Reconstructive Pelvic Surgery · Litchfield Park, AZNPI 1801213731
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,822 of the $4,371 with a category attached, or 87.5%. 22 manufacturers reported payments, led by Caldera Medical, Inc at 46.7% of the total. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in AZ, where the typical reported total is $8,817.
Across 172 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$2K
- Astellas Pharma US Inc$556
- Medtronic$473
- Femselect Inc.$231
- AbbVie$145
- Coloplast$129
- plus $797 from 16 others
What the payments were for
- Food & beverage$3,82287%
- Education$3889%
- Gifts$1614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 102 | $2,039 |
| Astellas Pharma US Inc | 11 | $556 |
| Medtronic | 6 | $473 |
| Femselect Inc. | 2 | $231 |
| AbbVie(2 entities) | 7 | $145 |
| Coloplast | 8 | $129 |
| 180 Medical, Inc. | 6 | $119 |
| Coopersurgical, Inc. | 1 | $119 |
| Boston Scientific | 5 | $94 |
| Axonics, Inc. | 4 | $85 |
| Urovant Sciences Inc | 3 | $55 |
| Johnson & Johnson | 2 | $51 |
| Pfizer | 3 | $42 |
| Olympus America Inc. | 2 | $35 |
| Rochester Medical Corporation | 2 | $35 |
| Therapeuticsmd, Inc. | 2 | $35 |
| Tolmar, Inc. | 1 | $28 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Millicent US Inc | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,371 in reported general payments places this provider in the 15th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Arizona.
See all urogynecology and reconstructive pelvic surgery providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 279 | $203,518 |
| MyrbetriqMirabegron | 175 | $149,354 |
| Estradiol | 512 | $34,446 |
| Solifenacin Succinate | 178 | $8,334 |
| Trospium Chloride | 120 | $5,232 |
| Methenamine Hippurate | 30 | $3,697 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 19 | $2,979 |
| Darifenacin ErDarifenacin Hydrobromide | 22 | $2,724 |
| Trimethoprim | 35 | $2,496 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $2,391 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 26 | $2,334 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 204 | $2,118 |
| Cephalexin | 160 | $1,708 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 52 | $1,545 |
| Ciprofloxacin Hcl | 357 | $1,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $15 | $203,518279 claims |
| Astellas Pharma US IncMyrbetriq | $556 | $149,354175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Arizona.
Other urogynecology and reconstructive pelvic surgery in Litchfield Park
- Jennifer KlauschieLitchfield Park$95K
- Christina RogersLitchfield Park$9K
- Keri WongLitchfield Park$9K
- Suzette SutherlandScottsdale$354K
- Gina CliettOro Valley$76K
- Anthony GaddiGilbert$72K
- Felipe VidelaPhoenix$25K
- Kelly KantartzisMesa$21K
- Daniel StonePhoenix$20K
- Mohammad IslamScottsdale$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.